Argos Therapeutics Announces Update on Phase 3 ADAPT Trial to be Presented During 2015 ASCO Genitourinary Cancers Symposium

DURHAM, N.C., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that an update on the company's Phase 3 ADAPT clinical trial of AGS-003 plus sunitinib for the treatment of metastatic renal cell carcinoma (mRCC) will be presented at the 2015 American Society of Clinical Oncology Genitourinary Cancers Symposium being held at Rosen Shingle Creek in Orlando, Florida.

Principal investigator Dr. Robert Figlin, the Steven Spielberg Family chair in hematology oncology and professor of medicine and biomedical sciences at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute in Los Angeles, California, will provide an update on enrollment to the ongoing ADAPT Phase 3 trial and highlight future directions for AGS-003 development during "General Session 8: Update on Current Clinical Trials" on Saturday, February 28 beginning at 1:45pm ET.

"There is strong rationale for combining AGS-003 and sunitinib for the treatment of mRCC that is supported by the encouraging survival data from the completed Phase 2 trial," said Dr. Figlin. "We hope to confirm these results with the ongoing Phase 3 ADAPT study and look forward to the first planned interim analysis by early June. Future development efforts with this fully personalized immunotherapy will focus on combinations with novel immunotherapy approaches and studies in earlier stages of RCC and other solid tumors."

During the presentation Dr. Figlin will provide an update on enrollment to the Phase 3 ADAPT trial, which is expected to complete enrollment to the tumor collection phase by spring 2015. Overall, at least 450 patients are expected to be randomized and initiate study treatment by summer 2015.

About the Arcelis® Technology Platform

Arcelis® is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized cancer immunotherapies. The Arcelis® process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease specific antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of HIV, currently being evaluated in a phase 2 clinical trial in combination with a latency reversing drug for HIV eradication in adult patients. For more information about Argos Therapeutics, visit

Forward Looking Statements

Any statements in this press release about Argos' future expectations, plans and prospects, including statements about Argos and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including whether Argos' cash resources will be sufficient to fund our continuing operations for the period anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Argos' Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 which is on file with the SEC. In addition, the forward-looking statements included in this press release represent Argos' views as of February 27, 2015. Argos anticipates that subsequent events and developments will cause Argos' views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Argos' views as of any date subsequent to February 27, 2015.

CONTACT: Media contact: Adam Daley Berry & Company Public Relations 212-253-8881 Investor contact: Nancy Yu Burns McClellan 212-213-0006

Source:Argos Therapeutics, Inc.